Research programme: immune checkpoint anticancer therapies - Shire/SymphogenAlternative Names: Immune checkpoint therapies - Shire/Symphogen
Latest Information Update: 15 Jun 2016
At a glance
- Originator Baxalta; Symphogen
- Developer Shire; Symphogen
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Checkpoint kinase inhibitors; Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer